[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mild-depression\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mild-depression":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100652742","effect-of-probiotic-on-cognitive-function-100652742",false,"NCT07776145","Effect of Probiotic on Cognitive Function","Effect of Probiotic Supplementation on Cognitive Function and Gut-Brain Axis Modulation in Females With Mild Depression","Inclusion Criteria:\n\nFemales, aged 50-64 years\n\n* Presence of mild depressive symptoms, defined as a Beck Depression inventory II (BDI-II) total score between 14 and 19 (inclusive) at the screening visit.\n* Ability to give informed consent\n\nExclusion Criteria:\n\n* Moderate and severe depression (BDI-II score \\> 19) or active suicidal ideation (assessed by clinical interview).\n* Diagnosis of bipolar disorder, schizophrenia, or other major psychotic disorder.\n\nCurrent use of antidepressants, antipsychotics, mood stabilizers, or regular anxiolytics\n\n* Regular consumption of probiotics, prebiotics, or synbiotic supplements within the past 4 weeks.\n* Use of antibiotics or antifungals within the past 4weeks.\n* Known diagnosis of inflammatory bowel disease, celiac disease, or active irritable bowel syndrome with severe symptoms.\n* History of significant cardiovascular disease (e.g., atrial fibrillation, heart failure, recent MI), uncontrolled hypertension, or type 1 diabetes.\n* Current use of systemic hormone replacement therapy within the last 3 months.Research Template 6 Final Version: Jan 2024\n* Known allergy to any component of the probiotic or placebo.\n* Severe systemic illness (e.g., uncontrolled diabetes, malignancy, severe hepatic, renal disease or auto-immune diseases).\n* CRP more than 10","FEMALE","50 Years","64 Years",{"count":20,"type":21},88,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if daily single-strain probiotic supplementation (Lactobacillus plantarum) works to improve cognitive function and depressive symptoms in Egyptian women aged 50-64 years with mild depression. It will also learn about its effects on systemic inflammation and autonomic nervous system function via the gut-brain axis\n\nThe main questions it aims to answer are:\n\nDoes a 12-week probiotic supplementation improve cognitive function (measured by MoCA-B) compared to a placebo? Does it reduce the severity of depressive symptoms (measured by BDI-II)? Does it reduce systemic inflammation (measured by hs-CRP levels in the blood)? Does it enhance autonomic nervous system function (measured by Heart Rate Variability - HRV via a smartphone app)? Researchers will compare the probiotic capsule (Lactobacillus plantarum, 10 billion CFU) to a placebo (a look-alike capsule containing starch) to see if the probiotic works better than placebo.\n\nParticipants will:\n\nTake one probiotic or placebo capsule orally every morning with breakfast for 12 weeks.\n\nVisit the Family Medicine outpatient clinic at baseline and at 12 weeks for cognitive and psychological tests, HRV measurements, and blood tests.\n\nReceive weekly follow-up messages on WhatsApp to monitor adherence and report any dietary changes or potential side effects.",[27,28],"Cognition Function","Mild Depression","NOT_YET_RECRUITING","2026-08-18",{"date":32,"type":33},"2026-08-20","ACTUAL",{"date":35,"type":21},"2026-09",{"date":37,"type":21},"2027-10",{"name":39,"class":40},"Cairo University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":41},"100628687","phase-3-prefrontal-glutamatergic-modulation-by-nac-and-mbct-for-depression-in-youth-100628687","NCT07464886","Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth","Prefrontal Glutamatergic Modulation by N-acetylcysteine and Mindfulness-based Cognitive Therapy for Mild Depression in Youth","NAC+MIND","Inclusion Criteria:\n\n1. age between 15 years, 0 months to 24 years, 11 months old;\n2. presenting with mild depression, defined by meeting DSM-5 criteria for a current major depressive episode, mild severity, or persistent depressive disorder, or other specified depressive disorder (depressive episode with insufficient symptoms to meet criteria for a major depressive episode);\n3. medication-naïve or medication free for at least 5 half-lives since the last use of a psychoactive medication, with the exception of stimulants for ADHD;\n4. if on ADHD stimulant medication over 2 months prior to screening, willing to maintain stimulant dose constant during the study participation;\n5. Tanner stage greater than or equal to III;\n\nExclusion Criteria:\n\n1. significant suicidal risk, defined by suicidal ideation of type 3, 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS) in the past 3 months, or any lifetime suicidal attempts;\n2. current major depressive episode, moderate or severe\n3. current or lifetime history of manic or hypomanic episodes, and\u002For diagnosis of bipolar disorder;\n4. current or lifetime history of psychotic disorders, and\u002For prior diagnosis of schizophrenia spectrum disorders;\n5. active or current substance use disorders in the last 3 months, except cannabis or alcohol use disorder, mild;\n6. diagnosis of autism spectrum disorder, pervasive developmental disorder, obsessive-compulsive disorder, post-traumatic stress disorders, Tourette's syndrome\n7. any contraindication to MRI scanning;\n8. pregnancy;\n9. history of major neurological disorder (e.g, epilepsy), or head trauma with \\> 10 minutes loss of consciousness;\n10. intellectual disability (IQ less than or equal to 70), as determined by the Weschler Abbreviated Scale of Intelligence (WASI);\n11. previous participation in any mindfulness-based treatment;\n12. initiating psychotherapy within 2 months prior to screening, or planning to initiate psychotherapy during study participation; if on therapy, frequency and type should remain stable for 2 months prior to enrollment and during study participation;\n13. no current diagnosis of asthma\n14. history of allergic reaction to N-acetylcysteine","ALL","15 Years","24 Years",{"count":54,"type":21},160,[56],"PHASE3","The primary goal is to investigate to what extent changes in glutamate and glutathione modulation and functional integration between brain networks associated with emotion and attention regulation are associated with treatment response in mildly depressed youth.",[28],[60,61,62,63,64,65,66],"Depression","adolescent","young adult","youth","mindfulness-based cognitive therapy","N-acetylcysteine","double-blind placebo controlled","RECRUITING","2026-03-06",{"date":70,"type":33},"2026-03-11",{"date":72,"type":33},"2026-02-26",{"date":74,"type":21},"2030-12",{"name":76,"class":40},"University of Cincinnati"]